Zr-Df-Pembrolizumab. In the humanized mouse model, Tcell infiltration into the salivary and lacrimal glands could be successfully visualized. Conclusion: These data will augment our understanding of the pharmacokinetics and biodistribution of radiolabeled pembrolizumab in vivo, while providing detailed dosimetry data that may lead to better dosing strategies in the future. These findings further demonstrate the utility of noninvasive in vivo PET imaging to dynamically track T-cell checkpoint receptor expression and localization in a humanized mouse model.
INTRODUCTION
Over the last five years, immunotherapies have shown remarkable success for the treatment of many cancers. Cancer immunotherapies encompass a broad range of therapeutic approaches with a similar end goal, namely directing the body's immune system to kill tumor cells (1) . However, as cancers derive from patients' own cells, tumor cells maintain many natural autoimmune defense mechanisms that can prevent tumor immune destruction. Disruption of these autoimmune defensive mechanisms has been shown to be remarkably successful at eliciting anti-tumor responses against many types of cancers (2) . Two of these most studied pathways, known as immune checkpoint pathways, are the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways. Both CTLA-4 and PD-1 are receptors expressed on the surface of activated T-cells which, when ligated, lead to the repression of cytolytic T-cell expansion and/or activity (2) . Antibodies preventing the ligation of both receptors have shown marked anti-tumor activity and have received FDA approval for the treatment of several malignancies (1).
One such antibody specific for PD-1 is pembrolizumab (Keytruda ® , Merck), a humanized IgG4 monoclonal antibody approved for the treatment of advanced melanoma and non-small cell lung cancer, and with early promising results observed in other malignancies as well (3) . In clinical trials, pembrolizumab displayed a 32% overall response rate in melanoma patients previously treated with ipilimumab, 21% higher than the response rate of patients receiving traditional chemotherapy (4, 5) . However, despite fewer toxicities than ipilimumab and traditional chemotherapies, excessive accumulation of PD-1 antibodies in the liver and kidneys has limited the use of these agents in some patients (6) . As only a subset of patients respond to anti-PD-1 therapies, and as their use is not without the risk of side effects, more work is needed to better understand the pharmacokinetic properties of these antibodies in vivo to identify optimal dosing strategies to provide the best chance of clinical benefit. Additionally, the ability to monitor PD-1 levels and localization in a dynamic fashion using a noninvasive imaging modality could prove useful at predicting for and monitoring responses to PD-1 targeted therapies.
There have been limited investigations into the imaging of checkpoint blockades. Recently, two studies employed different murine PD-1 antibodies, radiolabeled with 64 Cu, for imaging PD-1-expressing tumor-infiltrating by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from lymphocytes in murine models of melanoma (7, 8) . In this work, we investigate the biodistribution of a humanized PD-1 antibody in vivo. To our knowledge, this is the first study to investigate the pharmacokinetics, biodistribution, and dosimetry of radiolabeled pembrolizumab, a humanized antibody targeting PD-1, in vivo. To that end, we employed positron emission tomography (PET) imaging to map the biodistribution of pembrolizumab radiolabeled with the positron-emitting radionuclide zirconium-89 ( 89 Zr) in two normal rodent models. These data were extrapolated to human subjects to estimate radiation dosimetry to normal tissues. Additionally, the biodistribution and pharmacokinetics were assessed in a humanized mouse model implanted with human peripheral blood mononuclear cells (PBMCs). The humanized model showed a biodistribution profile differing from normal mice, allowing for effective visualization and mapping of PD-1-expressing cells in vivo using noninvasive PET imaging.
METHODS AND MATERIALS

In Vitro Binding Assay
Human PBMCs were isolated from blood samples collected under an institutional review board-approved protocol from patients giving informed consent via density gradient centrifugation using Ficoll-Histopaque (GE Healthcare, Little Chalfont, UK). PBMCs were thawed, washed, and resuspended at a concentration of 2x10 6 cells/mL in AB Media (RPMI-1640 + 10% AB sera/2% Penicillin-Streptomycin/1% NaPyr/0.1% βME) and stimulated with phorbol myristate acetate (40 ng/mL, Sigma, St. Louis, MO, USA) and ionomycin (1.3 ug/mL, MP Biomedicals, Santa Ana, CA, USA) for 18 h. Cells were washed and stained with the indicated concentration of pembrolizumab or Df-pembrolizumab for 1 h at 4°C. Cells were then washed and stained with 2 μg/mL AlexaFluor488-anti-human IgG secondary antibody (Life Technologies, Carlsbad, CA, USA), as well as CD3-v500, CD4-PE, and CD8-APC antibodies (BD Biosciences, San Jose, CA, USA) at a concentration of 2 tests / mL and a 1:1000 dilution of GhostDye Red-780 (Tonbo Biosciences, San Diego, CA, USA). Cells were washed, resuspended in FACS Wash (phosphate buffered saline/3% FCS) and analyzed on a BD LSRFortessa cytometer. The gating strategy was: Alive/FSCxSSC/Singlets/CD3+ and CD4 or CD8+. The PD-1 positive gate was determined using both no primary and no secondary antibody control-stained samples. (9, 10) . 89 Zr was produced in a biomedical cyclotron (GE PETtrace) via irradiation of natural yttrium foils (250 μm, 99.9%) with 16.4 MeV protons as previously described (11) . Radiolabeling of Df-Pembrolizumab with 89 Zr was accomplished using traditional methods previously described and purified with PD-10 columns (12).
Conjugation
Animal Models
All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. Mice and rats were used for examining the biodistribution, pharmacokinetics, and 
Radiation Dosimetry Extrapolation to Humans
Dosimetry analysis was performed using OLINDA/EXM software (13) . Estimated human dosimetry was calculated based on average %ID/g values from the serial PET scans on both mice and rats, which were converted to %ID in humans. It was assumed that the biodistribution in adult humans was the same as in the animal models, and a mono-exponential model was utilized for the time-activity curves. OLINDA provides effective dose outputs; thus, weighting factors from International Commission on Radiological Protection Publication 103 were employed to convert to absorbed dose in each organ (14) .
Statistical analysis
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Quantitative data were expressed as mean ± standard deviation with all error bars denoting the standard deviation. Means were compared using the Student t-test and p-values < 0.05 were considered statistically significant.
RESULTS
Binding of pembrolizumab to CD4+ and CD8+ T-cells
A binding assay of pembrolizumab to CD4+ and CD8+ T-cells was carried out to ensure that that Df chelation of pembrolizumab did not hinder or alter its binding affinity or specificity. T-cells were stimulated for 18 h before the addition of pembrolizumab or Df-pembrolizumab. Chelated pembrolizumab was shown to bind specifically to activated CD4+ T-cells and that chelation did not substantially alter its binding affinity for these activated cells (Fig. 1A) . Similar results were observed for CD8+ T-cells (Fig. 1B) .
Chelation and Radiolabeling of Pembrolizumab
Post-radiolabeling, the purified 89 Zr-Df-Pembrolizumab was shown to be labeled with a specific activity of 740 mBq/mg antibody. Labeling efficiency was determined by instant thin-layer chromatography and shown to be greater than 60%. Mice were injected with a lower activity of 89 Zr-Df-Pembrolizumab (5-10 MBq) in comparison to rats (37 MBq).
PET imaging and Biodistribution of 89
Zr-Df-Pembrolizumab in Mice
Longitudinal PET imaging studies were performed for seven days followed by animal euthanasia for biodistribution studies. Sequential PET images are presented as maximum intensity projections (MIPs) (Fig. 2A) .
ROI analysis of PET imaging was used to quantify the biodistribution ( Fig. 2B ; Supplemental Table 1 
Zr-Df-Pembrolizumab remained stable in blood circulation at 168 h post-injection (Fig. 2C) . The quantitative PET analysis of the liver, spleen, and kidneys showed similar %ID/g at 168 h post-injection. Organs with the lowest accumulation of 89 Zr-Df-Pembrolizumab at 168 h were the pancreas, stomach, intestines, and brain.
PET Imaging and Biodistribution of 89
Zr-Df-Pembrolizumab in Rats
Longitudinal PET imaging studies were performed for seven days, and representative MIPs were obtained for analysis (Fig. 3A) . The blood circulation of by 168 h post-injection (n=4). Ex vivo biodistribution showed similar findings to the PET imaging data, with the blood pool displaying the highest radioactivity at 168 h post-injection (Fig. 3C ). In addition, the liver, spleen, and kidneys showed similar accumulation, with muscle having the lowest uptake. In both mice and rats, bone uptake was similar to uptake in the liver, spleen, and kidneys. This phenomenon was expected, as non-chelated 89 Zr displays a strong affinity for phosphate and acts as a bone seeker in vivo (15) .
PET Imaging of PD-1 Expression in a Humanized Murine Model
As a proof-of-concept, the biodistribution of Tables 3 and 4) . However, there were two main by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from differences between the tracer biodistribution in PBL and NSG mice (Figs. 5A and 5B). First, PBL mice showed a shorter blood circulation in comparison to NSG mice. A statistically significant difference was found between the blood pool activity of NSG (9.78 ± 0.80 %ID/g) and PBL (6.13 ± 0.41 %ID/g) mice at 48 h and continued through 168 h post-injection (n=4). Second, the PBL mice displayed high uptake in the salivary glands. This difference in tracer accumulation was statistically significant at 6 h and each time point afterward (Fig. 5C) . Lastly, ex vivo distribution confirmed the PET imaging data, showing differences in tracer uptake by the blood pool and salivary glands (Supplemental Fig. 1 ). In addition, biodistribution showed a significant difference in liver accumulation, which could not be effectively delineated through PET ROI analysis (Fig. 5D) . Histological studies further validated that the salivary glands of PBL mice contained human T-cells expressing PD-1 through staining of the T-cell marker CD3 and PD-1, while NSG mice showed minimal staining as expected (Fig. 6 ).
Radiation Dosimetry
Estimations of human absorbed doses to normal tissues, based on the biodistribution of Low doses to the kidneys (0.025 mGy/MBq in mice and 0.017 mGy/MBq in rats) were calculated. Interestingly, the dose to the ovaries was highest, which may be of concern given the high radiosensitivity of the gonads. The total whole-body effective dose (0.515 ± 0.005 from mice and 0.540 ± 0.008 from rats) from the administered Zr-labeled PD-1 antibody as a radiotracer in rodent models. We used PET imaging to monitor antibody organ uptake over time and used these results to estimate human dosimetry from these data.
Further, we demonstrated in a humanized mouse model the specific binding of One important limitation of this work is that several studies have shown that preclinical investigation of antibody biodistribution in rodent models greatly varies from the observed kinetics in human patients (17) . High uptake in the liver and spleen in both mice (Fig. 2) and rats (Fig. 3) were likely a result of expected nonspecific binding and hepatobiliary clearance (18) . These intramodel differences are a limitation to the successful translation of some therapeutic antibodies, yet data obtained from rodent models may be extrapolated to humans through dosimetry analysis. This provides essential information regarding the expected human internal radiation doses to normal organs associated with the administration of radiolabeled antibodies. While all animals maintain similar biological machinery for the metabolism and elimination of drugs, these metabolic capabilities differ between different animal species (17) . For example, it has been shown that mice and rats display enhanced biliary excretion rates, while humans and other primates exhibit poor biliary excretion of most drugs (17, 19) . Dosimetry data may help predict potential toxicities before they occur in humans, while also assisting scientists in determining optimal initial dosing strategies when needed. The pattern of absorbed dose values obtained in this study indicates that this agent localizes in several tissues, further confirming the optimal circulation and low toxicity profile found in clinical trials.
As a proof-of-concept, we demonstrated that (20) . While these humanized mice gradually develop allogenic graft versus host disease, limiting their use for many therapy studies, the up-regulation of PD-1 during acute graft versus host disease made it possible to image the biodistribution of this immunotherapy target in our case (21) . Similar to our findings, several research groups have reported that engrafted immune cells infiltrate the salivary glands and lacrimal glands in PBL mice (22) (23) (24) . Thus, we expected that the PD-1 expressing T-cells would localize in the salivary glands of PBL mice, verifying that our PD-1 tracer was effective for imaging of PD-1-expressing T-cells in vivo. In this study, the salivary glands of PBL mice displayed the highest uptake of 89 Zr-Df-Pembrolizumab of 11.13 ± 0.82 %ID/g at 168 h post-injection, while NSG mice showed only 5.03 ± 0.59 %ID/g at the same time point (Fig. 5; n=4) . Thus, this study successfully demonstrated the ability to use a noninvasive immunotherapeutic-based imaging agent to monitor PD-1 localization and expression in vivo. This could allow researchers to potentially evaluate T-cell trafficking in vivo, and possibly to monitor for evidence of autoimmune adverse events by accumulation of PD-1-specific tracer at target sites prior to the development of overt symptoms. Further, we demonstrate that the use of humanized animal models may provide unique avenues for further imaging investigations of cancer immunotherapies.
In the future, an investigation into the correlation between PD-1 expression and tracer uptake may provide insight into methods for enhancing treatment protocols, further enhancing potential patient stratification. The future of immunotherapy is continually expanding, as researchers search for novel immune checkpoint molecules beyond PD-1 and CTLA-4. Some heavily investigated candidates include T-cell immunoglobulin mucin-3 (TIM-3), B and T lymphocyte attenuator, and lymphocyte activation gene-3 (LAG-3) (25) . Central to the clinical development of these novel T-cell checkpoint antibodies are questions surrounding proper dosage and timing, in addition to identifying patient populations more likely to respond to these therapies. We believe the use of radiolabeled variants of these antibodies for noninvasive PET imaging, specifically in the humanized PBL mouse model, could provide useful predictive data to assist in the clinical development of these novel immunotherapy agents.
CONCLUSION
Herein, this study provided the initial evidence that radiolabeled pembrolizumab circulates in animal models for an extended period, accumulating in expected tissues and organ systems. The pharmacokinetics, 
